Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13507373 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL30141059 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL9101384 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL30141075 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL13507904 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL4640426 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL24983638 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL13507688 | 1.00 | CYP3A4 (0.50) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL13117276 | 0.91 | CYP3A4 (0.58) | CYP3A4MAPK1ABCB1STING1BACE1 | |
| SCHEMBL9103972 | 0.91 | CYP3A4 (0.58) | CYP3A4MAPK1ABCB1STING1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | MARS, INCORPORATED (US) | 2010-02-25 | — | — | US | claimed |
| US-20080306286-A1 | Isolation, Purification and Synthesis of Procyanidin B2 and Uses Thereof | PROTAMED, INC. | 2008-12-11 | — | — | US | claimed |
| EP-1921076-A1 | systhesis of procyanidin B2 | Proteotech Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1896443-A1 | PREPARATION OF (+)-CATECHIN, (-)-EPICATECHIN, (-)-CATECHIN, (+)-EPICATECHIN, AND THEIR 5,7,3',4'-TETRA-O-BENZYL ANALOGUES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1896444-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4 , 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070276147-A1 | Synthesis of Oligomeric Epicatechin- and Catechin-Derived Procyanidins | KOZIKOWSKI ALAN P | 2007-11-29 | — | — | US | claimed |
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | claimed |
| US-7268240-B2 | Synthetic methods for polyphenols | MARS, INC. | 2007-09-11 | — | — | US | claimed |
| US-7244855-B2 | Synthesis of oligomeric epicatechin and catechin-derived procyanidins | MARS, INC. | 2007-07-17 | — | — | US | claimed |
| WO-2007005248-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4β, 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2007-01-11 | — | — | WO | claimed |
| US-7067679-B2 | Synthesis of dimeric, trimeric, tetrameric pentameric, and higher oligomeric epicatechin-derived procyanidins having 4,8-interflavan linkages and their use to inhibit cancer cell growth through cell cycle arrest | MARS, INC. | 2006-06-27 | — | — | US | claimed |
| EP-1554270-A2 | ISOLATION, PURIFICATION AND SYNTHESIS OF PROCYANIDIN B2 AND USES THEREOF | Proteotech, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| US-20050020512-A1 | Synthesis of oligomeric epicatechin and catechin-derived procyanidins | MARS, INCORPORATED | 2005-01-27 | — | — | US | claimed |
| US-20040116718-A1 | Synthesis of dimeric, trimeric, tetrameric pentameric, and higher oligomeric epicatechin-derived procyanidins having 4beta,8-interflavan linkages and their use to inhibit cancer cell growth through cell cycle arrest | MARS, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004033448-A2 | ISOLATION, PURIFICATION AND SYNTHESIS OF PROCYANIDIN B2 AND USES THEREOF | PROTEOTECH, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| JP-2004508362-A | — | — | 2004-03-18 | — | — | JP | claimed |
| EP-1317437-A2 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | Mars Incorporated (US) | 2003-06-11 | — | — | EP | claimed |
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | MARS INCORPORATED | 2003-05-29 | — | — | US | claimed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | claimed |
| WO-2002020506-A2 | SYNTHESIS OF 4α-ARYLEPICATECHINS | MARS, INCORPORATED (US) | 2002-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | FABP4, TEAD4, FABP7 | CYP3A4 300/4885MAPK1 2923/4885ABCB1 3807/4885 |
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | HAAO, TES, HPD | CYP3A4 249/4885MAPK1 2235/4885ABCB1 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.